IDH subgroup analysis showed that in IDH wild-type gliomas, the MGMT promoter-methylated group exhibited significantly higher values than the unmethylated group in ADCmin (0.84 ± 0.14 vs. 0.72 ± 0.11 ×10-3 mm2/s, p = 0.018), ADCmean (1.11 ± 0.18 vs. 0.98 ± 0.15 × 10-3 mm2/s, p = 0.021), rADCmin (1.10 ± 0.13 vs. 0.93 ± 0.09, p < 0.001), and rADCmean (1.38 ± 0.22 vs. 1.20 ± 0.18 × 10-3 mm2/s, p = 0.007). The gene discussed is MGMT; the disease is central nervous system cancer.